Busulfan (injection): Difference between revisions
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
No edit summary |
||
| Line 38: | Line 38: | ||
The drug was recently used in a study to examine the role of platelet-transported [[serotonin]] in [[liver]] regeneration.<ref>{{cite journal | author = Lesurtel M, Graf R, Aleil B, Walther D, Tian Y, Jochum W, Gachet C, Bader M, Clavien P | title = Platelet-derived serotonin mediates liver regeneration | journal = Science | volume = 312 | issue = 5770 | pages = 104–7 | year = 2006 | id = PMID 16601191}}</ref> | The drug was recently used in a study to examine the role of platelet-transported [[serotonin]] in [[liver]] regeneration.<ref>{{cite journal | author = Lesurtel M, Graf R, Aleil B, Walther D, Tian Y, Jochum W, Gachet C, Bader M, Clavien P | title = Platelet-derived serotonin mediates liver regeneration | journal = Science | volume = 312 | issue = 5770 | pages = 104–7 | year = 2006 | id = PMID 16601191}}</ref> | ||
===Pill Images=== | |||
{{TempDrugImages}} | |||
{{PillImage|fileName=MYLERAN_NDC_763880713.jpg|drugName=MYLERAN|NDC=763880713|drugAuthor=Aspen Global Inc.|ingredients=BUSULFAN[BUSULFAN]|pillImprint=GX;EF3;M|dosageValue=2|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=7|pillScore=1}} | |||
{{PillImage|fileName=MYLERAN_NDC_01730713.jpg|drugName=MYLERAN|NDC=01730713|drugAuthor=GlaxoSmithKline LLC|ingredients=BUSULFAN[BUSULFAN]|pillImprint=GX;EF3;M|dosageValue=2|dosageUnit=mg|pillColor=White|pillShape=Round|pillSize=7|pillScore=1}} | |||
==Toxicity and side effects== | ==Toxicity and side effects== | ||
Revision as of 22:58, 16 July 2014
| File:Busulfan.svg | |
| File:Busulfan3d.png | |
| Clinical data | |
|---|---|
| [[Regulation of therapeutic goods |Template:Engvar data]] | |
| Pregnancy category |
|
| Routes of administration | Oral, parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 80% (oral) |
| Protein binding | 32.4% |
| Metabolism | Hepatic |
| Elimination half-life | 2.5 hours |
| Excretion | ? |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C6H14O6S2 |
| Molar mass | 246.304 g/mol |
Overview
Busulfan is a chemotherapy drug that is a cell cycle non-specific alkylating agent (slows the growth of cancer cells). More specifically it belongs to a subclass of alkylating agents known as alkyl sulfonates. It is marketed in the U.S. by GlaxoSmithKline under the brand name Myleran, and has been in clinical use since 1959. Busulfan is also available in an IV formulation marketed as Busulfex by PDL BioPharma, Inc. Its chemical designation is 1,4-Butanediol dimethanesulfonate.
Uses
Currently, its main uses are in bone marrow transplantation, especially in chronic myelogenous leukemia (CML), where it is used as a conditioning drug. Busulfan can control tumor burden but cannot prevent transformation or correct cytogenic abnormalities. Though not as common, it may also be used for Chronic Lymphocytic Leukemia (CLL).
Its mechanism of action through alkylation produces DNA-DNA and DNA-protein cross linking. The resulting covalent bonds inhibit DNA, RNA, and protein synthesis. The inhibition of DNA synthesis subsequently produces a cytotoxic effect.
The drug was recently used in a study to examine the role of platelet-transported serotonin in liver regeneration.[1]
Pill Images
{{#ask: Page Name::Busulfan (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }} {{#subobject:
|Page Name=Busulfan (injection) |Pill Name=MYLERAN_NDC_763880713.jpg |Drug Name=MYLERAN |Pill Ingred=BUSULFAN[BUSULFAN]|+sep=; |Pill Imprint=GX;EF3;M |Pill Dosage=2 mg |Pill Color=White|+sep=; |Pill Shape=Round |Pill Size (mm)=7 |Pill Scoring=1 |Pill Image= |Drug Author=Aspen Global Inc. |NDC=763880713
}}
{{#subobject:
|Page Name=Busulfan (injection) |Pill Name=MYLERAN_NDC_01730713.jpg |Drug Name=MYLERAN |Pill Ingred=BUSULFAN[BUSULFAN]|+sep=; |Pill Imprint=GX;EF3;M |Pill Dosage=2 mg |Pill Color=White|+sep=; |Pill Shape=Round |Pill Size (mm)=7 |Pill Scoring=1 |Pill Image= |Drug Author=GlaxoSmithKline LLC |NDC=01730713
}}
Toxicity and side effects
Toxicity may include interstitial pulmonary fibrosis, hyperpigmentation, seizures, hepatic (veno-occlusive disease) and wasting syndrome. Phenytoin may be used concurrently to prevent the seizures.
1,4-Butanediol dimethanesulfonate is listed by the IARC as a Group 1 carcinogen.
Busulfan also induces thrombocytopenia, a condition of lowered blood platelet count and activity.
Historical
Busulfan use to be the standard of treatment for Chronic Myeloid Leukemia (CML) until it was replaced with the new gold standard, Imatinib.
References
- ↑ Lesurtel M, Graf R, Aleil B, Walther D, Tian Y, Jochum W, Gachet C, Bader M, Clavien P (2006). "Platelet-derived serotonin mediates liver regeneration". Science. 312 (5770): 104–7. PMID 16601191.
External links
- Myleran (PDF prescribing information)
- Busulfex (PDF prescribing information)
- Detailed information
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents
- Orphan drugs